Clinical Trial Update: Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD [Phase 2]

View source ↗

Summary

A Phase 2 trial of tucatinib, trastuzumab, and capecitabine for HER2-positive leptomeningeal disease in metastatic breast cancer was terminated; results have be…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Leptomeningeal Carcinomatosis

Drugs mentioned

• Capecitabine (capecitabine)
• Trastuzumab (trastuzumab)
• Tucatinib (tucatinib)

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Metastatic Breast Cancer, Leptomeningeal Disease | Phase 2 | Status: TERMINATED | Results posted: 2023-02-08